JP2010524906A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524906A5
JP2010524906A5 JP2010503549A JP2010503549A JP2010524906A5 JP 2010524906 A5 JP2010524906 A5 JP 2010524906A5 JP 2010503549 A JP2010503549 A JP 2010503549A JP 2010503549 A JP2010503549 A JP 2010503549A JP 2010524906 A5 JP2010524906 A5 JP 2010524906A5
Authority
JP
Japan
Prior art keywords
oxidepyridin
cyclopropylmethoxy
carboxamide
dichloro
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010503549A
Other languages
English (en)
Japanese (ja)
Other versions
JP5386478B2 (ja
JP2010524906A (ja
Filing date
Publication date
Priority claimed from FR0702853A external-priority patent/FR2915100B1/fr
Application filed filed Critical
Publication of JP2010524906A publication Critical patent/JP2010524906A/ja
Publication of JP2010524906A5 publication Critical patent/JP2010524906A5/ja
Application granted granted Critical
Publication of JP5386478B2 publication Critical patent/JP5386478B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010503549A 2007-04-19 2008-04-16 パーキンソン病に伴う運動不全の治療のための4−シクロプロピルメトキシ−n−(3,5−ジクロロ−1−オキシドピリジン−4−イル)−5−(メトキシ)ピリジン−2−カルボキサミドの使用 Expired - Fee Related JP5386478B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
FR0702853 2007-04-19
PCT/FR2008/000534 WO2008145841A1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (3)

Publication Number Publication Date
JP2010524906A JP2010524906A (ja) 2010-07-22
JP2010524906A5 true JP2010524906A5 (cg-RX-API-DMAC7.html) 2010-11-18
JP5386478B2 JP5386478B2 (ja) 2014-01-15

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503549A Expired - Fee Related JP5386478B2 (ja) 2007-04-19 2008-04-16 パーキンソン病に伴う運動不全の治療のための4−シクロプロピルメトキシ−n−(3,5−ジクロロ−1−オキシドピリジン−4−イル)−5−(メトキシ)ピリジン−2−カルボキサミドの使用

Country Status (33)

Country Link
US (1) US20100130554A1 (cg-RX-API-DMAC7.html)
EP (1) EP2146714B1 (cg-RX-API-DMAC7.html)
JP (1) JP5386478B2 (cg-RX-API-DMAC7.html)
KR (2) KR101503942B1 (cg-RX-API-DMAC7.html)
CN (1) CN101663035B (cg-RX-API-DMAC7.html)
AR (1) AR066108A1 (cg-RX-API-DMAC7.html)
AT (1) ATE513548T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008257322B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0810444A2 (cg-RX-API-DMAC7.html)
CA (1) CA2684174C (cg-RX-API-DMAC7.html)
CL (1) CL2008001136A1 (cg-RX-API-DMAC7.html)
CY (1) CY1111840T1 (cg-RX-API-DMAC7.html)
DK (1) DK2146714T3 (cg-RX-API-DMAC7.html)
EA (1) EA019194B1 (cg-RX-API-DMAC7.html)
ES (1) ES2367408T3 (cg-RX-API-DMAC7.html)
FR (1) FR2915100B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20110666T1 (cg-RX-API-DMAC7.html)
IL (1) IL201448A (cg-RX-API-DMAC7.html)
JO (1) JO2678B1 (cg-RX-API-DMAC7.html)
MA (1) MA31367B1 (cg-RX-API-DMAC7.html)
ME (1) ME00935B (cg-RX-API-DMAC7.html)
MX (1) MX2009011284A (cg-RX-API-DMAC7.html)
MY (1) MY148092A (cg-RX-API-DMAC7.html)
NZ (1) NZ580482A (cg-RX-API-DMAC7.html)
PA (1) PA8776801A1 (cg-RX-API-DMAC7.html)
PL (1) PL2146714T3 (cg-RX-API-DMAC7.html)
PT (1) PT2146714E (cg-RX-API-DMAC7.html)
RS (1) RS51869B (cg-RX-API-DMAC7.html)
SI (1) SI2146714T1 (cg-RX-API-DMAC7.html)
TW (1) TWI439269B (cg-RX-API-DMAC7.html)
UY (1) UY31035A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008145841A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200907251B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150087252A (ko) * 2012-11-28 2015-07-29 사노피 4-(사이클로프로필메톡시)-n-(3,5-디클로로-1-옥시도피리딘-4-일)-5-메톡시피리딘-2-카복스아미드의 결정 형태의 제조 방법 및 이의 결정 형태
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物
US20250120957A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DK0711282T3 (da) * 1993-07-28 2002-09-16 Aventis Pharma Ltd Forbindelser som PDE IV og TNF inhibitorer
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
HUP0600103A2 (en) * 2001-03-02 2006-06-28 Bristol Myers Squibb Co Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
JP2005538972A (ja) * 2002-07-02 2005-12-22 メルク フロスト カナダ アンド カンパニー ジアリール置換エタンピリドンpde4阻害剤
DE602004032522D1 (de) * 2003-03-12 2011-06-16 Celgene Corp Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
AU2006257863A1 (en) * 2005-06-10 2006-12-21 F. Hoffmann-La Roche Ag Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Similar Documents

Publication Publication Date Title
JP2022058688A5 (cg-RX-API-DMAC7.html)
JP2009525343A5 (cg-RX-API-DMAC7.html)
JP2015523407A5 (cg-RX-API-DMAC7.html)
JP2010529118A5 (cg-RX-API-DMAC7.html)
JP2012532874A5 (cg-RX-API-DMAC7.html)
JP2010522137A5 (cg-RX-API-DMAC7.html)
JP2010536849A5 (cg-RX-API-DMAC7.html)
JP2007500154A5 (cg-RX-API-DMAC7.html)
JP2013542247A5 (cg-RX-API-DMAC7.html)
NZ605469A (en) Nalbuphine-based formulations and uses thereof
JP2021152008A5 (cg-RX-API-DMAC7.html)
JP2013511507A5 (cg-RX-API-DMAC7.html)
JP2008505857A5 (cg-RX-API-DMAC7.html)
JP2010518086A5 (cg-RX-API-DMAC7.html)
JP2006508953A5 (cg-RX-API-DMAC7.html)
JP2016539156A5 (cg-RX-API-DMAC7.html)
JP2013541583A5 (cg-RX-API-DMAC7.html)
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
JP2013516493A5 (cg-RX-API-DMAC7.html)
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
JP2005508963A5 (cg-RX-API-DMAC7.html)
JP2009517411A5 (cg-RX-API-DMAC7.html)
JP2009062388A5 (cg-RX-API-DMAC7.html)
JP2010524906A5 (cg-RX-API-DMAC7.html)